Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone vs quetiapine vs olanzapine for methamphetamine-induced psychosis
IRCT20160530028173N5Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of risperidone, quetiapine and olanzapine in stimulant-induced psychosis and methamphetamine use disorder (MUD) (3 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoints: Treatment of psychotic symptoms, Positive symptoms and 1 more. Started Nov 2023; status: completed.
02
Drugs
risperidonequetiapineolanzapine
03
Conditions
stimulant-induced psychosismethamphetamine use disorder (MUD)
Beyond the preview
Go deeper on IRCT20160530028173N5.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20160530028173N5.